Arovella Therapeutics Ltd has released a press release.
SUDA Completes Divestment of Subsidiary
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Divestment Of Non-Core Subsidiary
- New Analyst Report
- SUDA Completes Acquisition Of Anti-Cancer Agent
- SUDAs Licensee Submits Marketing Application
- SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
Later from Arovella Therapeutics
- HC Berlin Pharma Update
- SUDA expands dialogue with World Health Organisation
- SUDA announces update on ZolpiMist in USA and Canada
- SUDA Expands Patent Coverage For Sildenafil
- Shareholder Update
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics